

IOTest[®] 3
CD5-FITC /
CD23-PE /
CD19-ECD

REF A07710

25 tests; 0.5 mL
 20 µL / test



IOTest 3
Conjugated Antibodies



ENGLISH	Specifications of constituent 1	Specifications of constituent 2	Specifications of constituent 3
Specificity	CD5	CD23	CD19
Clone	BL1a	9P25	J3-119
Hybridoma	SP2/0-Ag14 x Balb/c	NS1 x Balb/c	NS1 x Balb/c
Immunogen	Lymphocytes from the human thoracic duct	EBV modified lymphoblastic line	Lymphoma cells SKLY 18
Immunoglobulin	IgG2a	IgG1	IgG1
Species	Mouse	Mouse	Mouse
Source	Ascites	Ascites	Ascites
Purification	Protein A affinity chromatography	Protein A affinity chromatography	Protein A affinity chromatography
Fluorochrome	Fluorescein isothiocyanate (FITC)	R Phycoerythrin (PE)	R Phycoerythrin-Texas Red®-X (EC D™)
λ excitation	488 nm	488 nm	488 nm
Emission peak	525 nm	575 nm	613 nm
Buffer	PBS pH 7.2 plus 2 mg / mL BSA and 0.1% NaN ₃		

USE

This fluorochrome-conjugated antibody mixture is suitable for multiparametric analysis using flow cytometry. It permits the detection of the expression of CD5, CD23 and CD19 antigens in leucocytes.

PRINCIPLE

This test is based on the ability of specific monoclonal antibodies to bind to the antigenic determinants expressed by leucocytes.

Specific staining of the leucocytes is performed by incubating the sample with the IOTest 3 reagent. The red cells are then removed by lysis and the leucocytes, which are unaffected by this process, are analyzed by flow cytometry. The flow cytometer analyzes light diffusion and the fluorescence of cells. It makes possible the localization of cells within the electronic window defined on a histogram, which correlates the orthogonal diffusion of light (Side Scatter or SS) with the fluorescence of ECD, corresponding to CD19 staining. Other histograms combining two of the different parameters available on the cytometer are also used in the gating stage. The cell population thus gated is subdivided into sub-populations, using the two other fluorescences.

In this way, the positively-stained cells are distinguished from the unstained cells. The results are expressed as a percentage of fluorescent cells in relation to all the events acquired by the gating.

EXAMPLES OF CLINICAL APPLICATIONS

The co-expression of CD5 and CD19 antigens enables B lymphoproliferative syndromes to be differentiated (CD5⁺CD19⁺) from T lymphoproliferative syndromes (CD5⁺CD19⁻) (1, 2).

The simultaneous analysis of CD5, CD19 and CD23 antigens makes possible a finer discrimination between the various B type proliferative syndromes such as the chronic B lymphoid leukaemias and small cell lymphomas, which are CD5⁺CD23⁺CD19⁺ and the mantle cell lymphomas, which are CD5⁺CD23⁻CD19⁺ (1 – 6).

STORAGE AND STABILITY

The conjugated liquid forms must be kept at between 2 and 8°C and protected from light, before and after the vial has been opened.

Stability of closed vial: see expiry date on vial.

Stability of opened vial: the reagent is stable for 90 days.

PRECAUTIONS

- Do not use the reagent beyond the expiry date.
- Do not freeze.
- Let it come to room temperature (18 – 25°C) before use.
- Minimize exposure to light.
- Avoid microbial contamination of the reagents, or false results may occur.
- Antibody solutions containing sodium azide (NaN₃) should be handled with care. Do not take internally and avoid all contact with the skin, mucosa and eyes. Moreover, in an acid medium, sodium azide can form the potentially dangerous hydrazoic acid. If it needs to be disposed of, it is recommended that the reagent be diluted in a large volume of water before pouring it into the drainage system so as to avoid the accumulation of sodium azide in metal pipes and to prevent the risk of explosion.
- All blood samples must be considered as potentially infectious and must be handled with care (in particular: the wearing of protective gloves, gowns and goggles).
- Never pipette by mouth and avoid all contact of the samples with the skin, mucosa and eyes.
- Blood tubes and disposable material used for handling should be disposed of in ad hoc containers intended for incineration.

SPECIMENS

Venous blood or bone marrow samples must be taken using sterile tubes containing an EDTA salt as the anticoagulant. The use of other anticoagulants is not recommended.

The samples should be kept at room temperature (18 – 25°C) and not shaken. The samples should be homogenized by gentle agitation prior to taking the test sample. The samples must be analyzed within 24 hours of venipuncture.

METHODOLOGY

NECESSARY MATERIAL NOT SUPPLIED

- Sampling tubes and material necessary for sampling.
- Automatic pipettes with disposable tips for 20, 100 and 500 µL.
- Plastic haemolysis tubes.
- Calibration beads: Flow-Set™ Fluorospheres (Ref. 6607007).

- To obtain optimal results, the following reagents are recommended:
 - Lysing reagent: IOTest 3 Lysis Solution (Ref. A07799).
 - Fixation reagent: IOTest 3 Fixative Solution (Ref. A07800).
 - One of the following IOTest 3 negative controls:
 - Neg-FITC/Neg-PE/CD19-ECD (Ref. A07730) or
 - Neg-FITC/Neg-PE/Neg-ECD (Ref. A07732).
 - Buffer (PBS: 0.01 M sodium phosphate; 0.145 M sodium chloride; pH 7.2).
 - Centrifuge.
 - Automatic agitator (Vortex type).
 - Flow cytometer.

PROCEDURE

For each sample analyzed, in addition to the test tube, one control tube is required in which the cells are mixed with the IOTest 3 negative control (Ref. A07730 or A07732).

- Add 20 µL of specific IOTest 3 conjugated antibodies to each tube, and 20 µL of the appropriate negative control to each control tube.
- Add 100 µL of total blood sampled in EDTA (or 5 x 10⁵ cells) in both tubes. Vortex the tubes gently.
- Incubate for 15 to 20 minutes at room temperature (18 – 25°C), protected from light.
- Then perform lysis of the red cells, if necessary, by adding 2 mL of IOTest 3 Lysis Solution (Ref. A07799) at its working concentration (1X). Vortex immediately and incubate for 10 minutes at room temperature, protected from light. If the sample does not contain red cells, add 2 mL of PBS.
- Centrifuge for 5 minutes at 300 x g at room temperature.
- Remove the supernatant by aspiration.
- Resuspend the cell pellet using 3 mL of PBS.
- Repeat stage 5.
- Remove the supernatant by aspiration and resuspend the cell pellet using:
 - 0.5 mL or 1 mL of IOTest 3 Fixative Solution (Ref. A07800) at its working concentration (1X), if the preparations are to be kept for more than 2 hours and for less than 24 hours,
 - 0.5 mL or 1 mL of PBS without formaldehyde, if the preparations are to be analyzed within 2 hours.
- NOTE: In all cases, keep the preparations between 2 and 8°C and protected from light.

PERFORMANCE

SPECIFICITY

The CD5 molecule is expressed at the surface of mature T lymphocytes, by the majority of thymocytes and by a sub-population of B lymphocytes (7–9). Its expression is not found in granulocytes, monocytes and platelets (9).

The monoclonal antibody (mAb) BL1a was assigned to CD5 during the 3rd HLDA Workshop on Human Leucocyte Differentiation Antigens, Oxford, England, in 1986 (Code WS: 520, Section T) (7, 8).

The CD23 antigen is expressed mainly on B lymphocytes and monocytes. It is also present in a wide variety of other cells, including T lymphocytes, eosinophils, neutrophils, platelets, Langerhans' cells and a sub-population of epithelial thymic cells. The expression of CD23 is regulated positively during activation of B lymphocytes and ceases during plasmocyte differentiation (10, 11).

MAb 9P25 was assigned to CD23 during the 6th HLDA Workshop held in Kobe, Japan, in 1996 (WS Code: CD23.1, Section B) (12).

The CD19 molecule is expressed on the surface of all cells of the B-line, from early pre-B-cells to mature B lymphocytes. Its expression is lost on differentiation into plasmocytes (13 – 15). Expression of CD19 is not observed in T lymphocytes, NK cells, monocytes or granulocytes (15).

MAb J3-119 was assigned to CD19 during the 4th HLDA Workshop, Vienna, Austria 1989 (16, 17).

LINEARITY

To test the linearity of staining for the specificities of this reagent, a positive cell line and a negative cell line were mixed in different proportions with a constant final number of cells, so that the positive line/negative line ratio of the mixture ranged from 0 to 100%.

Aliquots were stained using the procedure described above and linear regression between the expected values and the observed values was calculated.

Specificity	Linear regression	Linearity (R ²)
CD5	Y = 0.99 X + 0.34	0.999
CD23	Y = 0.99 X + 0.33	0.999
CD19	Y = 0.98 X + 1.22	0.999

EXPECTED VALUES

Each laboratory must compile a list of reference values based upon a group of healthy donors from the local population. This must be done by taking age, sex and ethnic group into account, as well as any other potential regional differences.

In our laboratories, the whole blood samples of 50 healthy adults were treated using the reagent described above. The mean values of the results obtained in the leucocyte sub-populations of interest in these 50 donors are shown in the tables below:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD5 ⁺	50	73.32	7.73	11
CD23 ⁺	50	7.70	4.05	53
CD19 ⁺	50	9.92	4.65	47

Monocytes	Number	Mean (%)	SD	CV (%)
CD23 ⁺	50	6.34	5.66	89

INTRA-LABORATORY REPRODUCIBILITY

On the same day and using the same cytometer, 12 measurements of the percentage of positive cells were carried out on a target population (lymphocytes) expressing these three markers. The results obtained are summarized in the following table:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD5 ⁺	12	70.78	0.42	0.60
CD23 ⁺	12	7.91	0.27	3.43
CD19 ⁺	12	13.01	0.33	2.53

INTER-LABORATORY REPRODUCIBILITY

On the same day and on the same target population (lymphocytes), 12 measurements of the percentage of positive cells were carried out by two technicians and the preparations analyzed using two different cytometers. The results obtained are summarized in the following tables:

Cytometer n°1:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD5 ⁺	12	70.78	0.42	0.60
CD23 ⁺	12	7.91	0.27	3.43
CD19 ⁺	12	13.01	0.33	2.53

Cytometer n°2:

Lymphocytes	Number	Mean (%)	SD	CV (%)
CD5 ⁺	12	71.53	0.32	0.40
CD23 ⁺	12	8.32	0.37	4.40
CD19 ⁺	12	12.62	0.29	1.00

LIMITATIONS OF THE TECHNIQUE

1. Flow cytometry may produce false results if the cytometer has not been aligned perfectly, if fluorescence leaks have not been correctly compensated for and if the regions have not been carefully positioned.
2. It is preferable to use a RBC lysis technique with a washing step as this reagent has not been optimized for "no wash" lysis techniques.
3. Accurate and reproducible results will be obtained as long as the procedures used are in accordance with the technical insert leaflet and compatible with good laboratory practices.
4. The conjugated antibodies of this reagent are calibrated so as to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/sample volume ratio in every test.
5. In the case of a hyperleucocytosis, dilute the blood in PBS so as to obtain a value of approximately 5×10^9 leucocytes/L.
6. In certain disease states, such as severe renal failure or haemoglobinopathies, lysis of red cells may be slow, incomplete or even impossible. In this case, it is recommended to isolate mononucleated cells using a density gradient (Ficoll, for example) prior to staining.

MISCELLANEOUS

See the Appendix for examples and references.

TRADEMARKS

The Beckman Coulter logo, COULTER, ECD, EPICS, EXPO, Flow-Set, IOTest, System II, and XL are the registered trademarks of Beckman Coulter Inc.

Texas Red is a registered trademark of Molecular Probes Inc.

MANUFACTURED BY:

IMMUNOTECH
a Beckman Coulter Company
130 avenue de Lattre de Tassigny
B.P. 177 – 13276 Marseille Cedex 9
France
Customer Services: (33) 4 91 17 27 27


www.beckmancoulter.com



EXAMPLES

The 4 diagrams below are biparametric representations (Side Scatter versus Fluorescence Intensity or Fluorescence Intensity versus Fluorescence Intensity) of a B-cell Chronic Lymphocytic Leukemia specimen (B-CLL, Peripheral blood). Staining is with CD5-FITC / CD23-PE / CD19-ECD Conjugated Antibodies (Ref. A07710). Lysis and fixation are with IOTest 3 Lysing Solution (Ref. A07799) and IOTest 3 Fixative Solution (Ref. A07800) respectively. All events acquired are shown. Region A defines the gating strategy (CD19 positive cluster) used on this example. Gated events are shown in dark in all histograms.

Acquisition is with a COULTER® EPICS® XL™ flow cytometer equipped with System II™ Software. Analysis is with EXPO™ Cytometer Software (Ref. 6605434).



REFERENCES

1. Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Höffkes, H.G., Janossy, G., Knüchel, R., Ludwig, W.D., Nebe, T., Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A., Wörmann, B., "Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies", 1996, *Leukemia*, 10, 877-895.
2. Jenning, C.D., Foon, K.A., "Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy", 1997, *Blood*, 90, 2863-2892.
3. Rosenberg, S.A., "Classification of lymphoid neoplasms", 1994, *Blood*, 84, 1359-1360.
4. Kilo, M.N., Dorfman, D.M., "The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma / chronic lymphocytic leukemia from mantle cell lymphoma", 1996, *Am. J. Clin. Pathol.*, 105, 451-457.
5. Borowitz, M.J., Bray, R., Gascoyne, R., Melnick, S., Parker, J.W., Picker, L., Stetler-Stevenson, M., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation", 1997, *Cytometry*, 30, 236-244.
6. Stewart, C.C., Behm, F.G., Carey, J.L., Cornbleet, J., Duque, R.E., Hudnall, S.D., Hurtubise, P.E., Loken, M., Tubbs, R.R., Wormsley, S., "U.S. Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations", 1997, *Cytometry*, 30, 231-235.
7. Horejsi, V., Angelisova, P., "Comparatives biochemical studies on the Workshop CD5 and CD3 panel antibodies", 1987, *Leucocyte Typing III, White Cell Differentiation Antigens*, McMichael A.J., et al., Eds., Oxford University Press, 197.
8. Disanto, J.P., Small, T.N., Dupont, B., Flomenberg, N., Knowles, R.W., "Analysis of human CD8 and CD5 antigens expressed on mouse L-lines", 1987, *Leucocyte Typing III, White Cell Differentiation Antigens*, McMichael A.J., et al., Eds., Oxford University Press, 210-214.
9. Reiter, C., "Cluster report: CD5", 1989, *Leucocyte Typing IV, White Cell Differentiation Antigens*. W. Knapp, et al., Eds., Oxford University Press, 331-332.
10. Bonnefoy, J.Y., Aubry, J.P., Peronne, C., Wijdenes, J., Banchereau, J., "Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE", 1987, *J. Immunol.*, 138, 2970-2978.
11. Goff, L.K., Armitage, R.J., Beverley, P.C.L., "Characterization of two CD23 monoclonal antibodies with reactivity distinct from other antibodies within this cluster of differentiation", 1988, *Immunology*, 65, 213-220.
12. Sarfati, M., "CD23 workshop panel report", 1996, *Leucocyte Typing VI, White Cell Differentiation Antigens*. Kishimoto, T., et al., Eds., Garland Publishing, 144-147.
13. Uckun, F.M., "Regulation of human B-cell ontogeny", 1990, *Blood*, 76, 1908-1923.
14. Loken, M.R., Shah, V.O., Dattilio, K.L., Civin, C.I., "Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development", 1987, *Blood*, 70, 1316-1324.
15. Pesando, J. M., Bouchard, L. S., McMaster, B. E., "CD19 is functionally and physically associated with surface immunoglobulin", 1989, *J. Exp. Med.*, 170, 2159-2164.
16. "CD Guide " Compiled by the organizing committee, 1989, *Leucocyte Typing IV, White Cell Differentiation Antigens*. W. Knapp, et al., Eds., Oxford University Press, 1078.
17. "Listing of all Fourth Workshop antibodies", 1989, *Leucocyte Typing IV, White Cell Differentiation Antigens*. W. Knapp, et al., Eds., Oxford University Press, 1094-1110.